Trial Profile
Multicenter, Single Arm, Open-Label Phase II Trial On The Efficacy Of Ortataxel In Recurrent Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2019
Price :
$35
*
At a glance
- Drugs Ortataxel (Primary) ; Fotemustine
- Indications Astrocytoma; Glioblastoma
- Focus Therapeutic Use
- 21 Oct 2019 Status has bben changed to completed.
- 09 Feb 2016 Planned primary completion date changed from 1 Mar 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
- 09 Feb 2016 Status changed from recruiting to suspended as per ClinicalTrials.gov record.